Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:NLTX NASDAQ:ORIC NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.47+1.2%$34.46$29.19▼$50.79$1.20B0.73409,094 shs646,719 shsNLTXNeoleukin Therapeutics$35.34+4.3%$29.17$2.03▼$14.36$332.13M1.1150,104 shs363,217 shsORICOric Pharmaceuticals$10.91-6.3%$8.92$7.23▼$14.93$1.20B1.021.63 million shs2.62 million shsPURRHyperliquid Strategies$8.82+9.6%$8.07$3.01▼$11.62$1.16B1.6614.19 million shs8.64 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+1.19%+4.14%+12.25%+14.38%+23.38%NLTXNeoleukin Therapeutics0.00%+10.33%+33.41%+72.64%+75.91%ORICOric Pharmaceuticals-6.27%+7.49%+45.47%+23.00%+1.30%PURRHyperliquid Strategies+9.57%+4.13%+3.40%+80.37%+881,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.47+1.2%$34.46$29.19▼$50.79$1.20B0.73409,094 shs646,719 shsNLTXNeoleukin Therapeutics$35.34+4.3%$29.17$2.03▼$14.36$332.13M1.1150,104 shs363,217 shsORICOric Pharmaceuticals$10.91-6.3%$8.92$7.23▼$14.93$1.20B1.021.63 million shs2.62 million shsPURRHyperliquid Strategies$8.82+9.6%$8.07$3.01▼$11.62$1.16B1.6614.19 million shs8.64 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+1.19%+4.14%+12.25%+14.38%+23.38%NLTXNeoleukin Therapeutics0.00%+10.33%+33.41%+72.64%+75.91%ORICOric Pharmaceuticals-6.27%+7.49%+45.47%+23.00%+1.30%PURRHyperliquid Strategies+9.57%+4.13%+3.40%+80.37%+881,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.17Buy$57.5053.46% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/AORICOric Pharmaceuticals 2.76Moderate Buy$18.9273.39% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$12.7244.18% UpsideCurrent Analyst Ratings BreakdownLatest NLTX, COLL, PURR, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $18.406/29/2026COLLCollegium Pharmaceutical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/15/2026COLLCollegium Pharmaceutical Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/12/2026ORICOric Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/12/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.756/8/2026ORICOric Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/3/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/22/2026ORICOric Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/20/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D)5/20/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.45 ➝ $9.75(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$780.57M1.56$15.42 per share2.43$9.54 per share3.93NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/APURRHyperliquid Strategies$1M1,274.05N/AN/A$1.52 per share5.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$62.87M$2.0418.376.34N/A9.41%95.18%16.39%8/6/2026 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/AN/AN/AN/A-37.22%-30.91%N/AORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$7.37N/AN/AN/AN/A-56.04%-52.22%N/ALatest NLTX, COLL, PURR, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026COLLCollegium Pharmaceutical$1.52$1.76+$0.24$0.40$184.47 million$193.52 million5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical2.471.711.62NLTXNeoleukin TherapeuticsN/A15.3315.33ORICOric PharmaceuticalsN/A16.3316.33PURRHyperliquid StrategiesN/A18.2318.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ANLTXNeoleukin Therapeutics52.37%ORICOric Pharmaceuticals95.05%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical1.85%NLTXNeoleukin Therapeutics1.58%ORICOric Pharmaceuticals5.70%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.43 million31.83 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataORICOric Pharmaceuticals80103.52 million97.62 millionOptionablePURRHyperliquid StrategiesN/A144.45 million132.20 millionN/ANLTX, COLL, PURR, and ORIC HeadlinesRecent News About These CompaniesWhy Money Is Leaving Bitcoin for HyperliquidJuly 3, 2026 | aol.comAHyperliquid Strategies Inc (NASDAQ:PURR) Sees Significant Growth in Short InterestJuly 2, 2026 | americanbankingnews.comHyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI IndicesJune 29, 2026 | prnewswire.comHyperliquid Strategies Enhances Executive Compensation and Leadership StructureJune 26, 2026 | tipranks.comPanther Minerals Announces Brokered Private Placement of up to $3,000,000June 16, 2026 | accessnewswire.comAHyperliquid Strategies shares jump as HYPE token strength and late-June index reconstitution fuel buyingJune 16, 2026 | quiverquant.comQHyperliquid Strategies Stock Is Surging Tuesday: What's Driving The Action?June 16, 2026 | benzinga.comWhy Is Hyperliquid Strategies Stock Gaining Monday?June 15, 2026 | benzinga.comPanther Minerals Announces Appointment of Harrison Glancy to Board of DirectorsJune 10, 2026 | accessnewswire.comAHyperliquid Strategies (PURR) Is Down 14.6% After Gamma Squeeze Speculation and Index Inclusion Buzz – What's ChangedJune 7, 2026 | finance.yahoo.comComparing HYPE & PURR: The Most Stock-Like Crypto PlayJune 5, 2026 | seekingalpha.comArthur Hayes: My $100,000 Against Yours That SOL Will Not Outperform The Hottest Coin In The MarketJune 2, 2026 | benzinga.comPURR Stock On Track For Record High After Hyperliquid Flips Dogecoin To Enter Crypto Top 10June 1, 2026 | finance.yahoo.comHyperliquid Is 'Bigger Than Nasdaq,' Says ICE CEO — HYPE Eyes New Record High, While ETFs Top $100MMay 30, 2026 | finance.yahoo.comHyperliquid Strategies (PURR) jumps as Russell Microcap inclusion chatter lifts demandMay 29, 2026 | quiverquant.comQWhy Hyperliquid Strategies Inc.’s (PURR) Stock Is Up 12.26%May 28, 2026 | aaii.comAGoldman Sachs Sells XRP and SOL ETF, Pivots to Hyperliquid in Q1 2026May 22, 2026 | memeburn.comMHyperliquid token surges toward all-time high after spot ETF inflows hit record – 'Everything is down lately except HYPE,' says analystMay 22, 2026 | msn.comThe Token Takeover: SEC Triggers Market Quake (PURR)...May 21, 2026 | marketbeat.com21Shares has a new ETF—and it's in big demand (corrected)May 20, 2026 | msn.comCathie Woods' 21Shares Has A New ETF—And It's In Big DemandMay 19, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026GameStop’s $2 Billion Buyback Sends a Confusing Signal to InvestorsBy Thomas Hughes | June 10, 2026Qualcomm Drops 25%, But Investor Day Could Reverse the SlideBy Sam Quirke | June 15, 2026Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?By Nathan Reiff | June 29, 2026Why Kroger's Giant Eagle Deal Could Change EverythingBy Jeffrey Neal Johnson | July 3, 2026NLTX, COLL, PURR, and ORIC Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$37.47 +0.44 (+1.19%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$37.51 +0.04 (+0.10%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Neoleukin Therapeutics NASDAQ:NLTX$35.34 +1.46 (+4.31%) As of 07/2/2026Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Oric Pharmaceuticals NASDAQ:ORIC$10.91 -0.73 (-6.27%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$10.94 +0.03 (+0.23%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Hyperliquid Strategies NASDAQ:PURR$8.82 +0.77 (+9.57%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$8.73 -0.09 (-1.02%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
